Centene Surprises Wall Street With Q3 Profit, Stock Jumps Over 10%
- Centene’s shares jumped sharply Wednesday after the health insurance provider posted a surprise quarterly profit, defying expectations and signaling a potential turnaround in its ACA-driven business model.
- The earnings beat was powered by rising demand for Medicare prescription drug plans and stronger-than-expected Medicaid premium revenue, which helped offset prior concerns about exchange-based coverage.
Key Takeaways
Centene Corporation (CNC) stunned investors with a third-quarter adjusted earnings per share of $0.50, defying expectations of a loss. The company also raised its full-year adjusted EPS guidance to at least $2.00, up from its previous estimate of $1.75.
Key drivers behind the unexpected profit:
- Medicare prescription drug plans saw a surge in demand.
- Medicaid premiums increased, with a 40 basis point benefit from retroactive revenue adjustments from a large state.
- Commercial and Medicare segments performed in line with expectations.
Despite a $6.7 billion non-cash goodwill impairment that led to a GAAP loss, Centene’s operational performance exceeded forecasts, boosting investor confidence.
CEO Sarah London emphasized that the results reflect “tangible progress against the near-term milestones we laid out for investors in July,” signaling a potential turnaround after earlier concerns about Affordable Care Act exchange plans.
Market reaction:
- Centene shares jumped more than 10% in premarket trading following the announcement.
- The stock had previously plunged in July when the company withdrew its full-year outlook, but this rebound suggests renewed optimism.
Centene’s performance highlights how strategic adjustments in government-backed health plans can drive profitability even amid broader sector uncertainty.
Centene Stock Jumps 10% After Medicare and Medicaid Drive Surprise Q3 Profit
Centene (CNC) surged more than 10% in recent trading after the health insurance provider stunned Wall Street with a third-quarter profit and raised its full-year guidance. The company reported adjusted earnings of $0.50 per share, beating expectations of a loss, while revenue climbed 18.2% year-over-year to $49.69 billion, topping analyst estimates.
The upside was fueled by strong demand for Medicare prescription drug plans and higher Medicaid premiums, signaling renewed momentum in Centene’s government-backed insurance portfolio.
Centene’s stronger-than-expected earnings may represent a pivotal shift for the company, which faced a steep stock decline earlier this year due to uncertainty surrounding its Affordable Care Act exchange offerings. The Q3 profit and raised outlook suggest renewed stability in its government-backed insurance strategy.
Centene now expects full-year adjusted earnings per share of at least $2.00, up from its previous estimate of $1.75, signaling stronger-than-expected performance in its Medicare and Medicaid segments.
CEO Sarah London said the improved outlook reflects “tangible progress” on investor milestones set in July, despite earlier turbulence tied to Affordable Care Act exchange plans.
Centene’s stock, which plunged in July after withdrawing its prior forecast, remains down roughly 40% for the year even with this week’s rebound underscoring lingering investor caution around ACA-driven volatility.
